Wellthy Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 7.20 Cr
as on 17-11-2024
- Paid Up Capital ₹ 5.99 Cr
as on 17-11-2024
- Company Age 9 Year, 18 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -1.29%
(FY 2023)
- Profit 38.58%
(FY 2023)
- Ebitda 34.77%
(FY 2023)
- Net Worth -56.54%
(FY 2023)
- Total Assets 37.63%
(FY 2023)
About Wellthy Therapeutics
The Company is engaged in the Internet Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.20 Cr and a paid-up capital of Rs 5.99 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Wellthy Therapeutics Private Limited India is Abhishek Shah as CEO. Abhishek Shah, Prayat Shah, Amit Chhajer, and One other member serve as directors at the Company.
- CIN/LLPIN
U93030MH2015PTC270628
- Company No.
270628
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
- Apps
Who are the key members and board of directors at Wellthy Therapeutics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Shah  | CEO | 11-Aug-2017 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abhishek Shah | Director and Ceo | 02-Dec-2015 | Current |
| Prayat Shah | Director | 01-May-2024 | Current |
| Amit Chhajer | Nominee Director | 12-Jul-2024 | Current |
Mahdi Attya  | Nominee Director | 12-Jul-2024 | Current |
Financial Performance and Corporate Structure Insights of Wellthy Therapeutics.
Wellthy Therapeutics Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.29% decrease. The company also saw a substantial improvement in profitability, with a 38.58% increase in profit. The company's net worth observed a substantial decline by a decrease of 56.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wellthy Therapeutics?
In 2023, Wellthy Therapeutics had a promoter holding of 92.81% and a public holding of 7.19%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wellthy Therapeutics?
Wellthy Therapeutics has a workforce of 38 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wellthy Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wellthy Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
